4X reduction in childhood Primary Nocturnal Enuresis by Vitamin D
A Novel Approach to the Management of Children with Primary Nocturnal Enuresis
Children (Basel) 2025 Aug 27;12(9):1128. doi: 10.3390/children12091128.
Buket Esen Agar 1, Metin Kaya Gurgoze 2, Aslihan Kara 1
Nocturnal enuresis was defined as repeated involuntary urination during sleep occurring at least twice per week in children aged 5 years or older.Monosymptomatic PNE was defined as enuresis persisting for more than six months during sleep in the absence of bladder dysfunction or lower urinary tract symptoms
Nocturnal Enuresis significantly reduced by Vitamin D (2,400 IU daily for just 8 weeks) - RCT April 2026
Efficacy and Safety of High-Dose Vitamin D Supplementation Combined with an Enuresis Alarm vs Alarm Alone in Children with Primary Monosymptomatic Nocturnal Enuresis: A Randomized Clinical TrialJ Urol. 2026 Apr 29:101097JU0000000000005071. doi: 10.1097/JU.0000000000005071 PDF behind paywall
Zihan Ye 1 2 3 4 5 6 7 8, Xingguo Luo 1 2 3 4 5 6 7 8, Hongsong Chen 1 2 3 4 5 6 7 8, Qiang Zhang 1 2 3 4 5 6 7 8, Chang Li 1, Zhicheng Zhang 1 2 3 4 5 6 7 8, Shengde Wu 1 2 3 4 5 6 7 8, Deying Zhang 1 2 3 4 5 6 7 8, Yi Hua 1 2 3 4 5 6 7 8, Guanghui Wei 1 2 3 4 5 6 7 8, Xing Liu 1 2 3 4 5 6 7 8
Purpose: This study evaluated the efficacy and safety of high-dose vitamin D supplementation (VDS) combined with enuresis alarm (EA) therapy in children with primary monosymptomatic nocturnal enuresis (PMNE).
Materials and methods: A two-arm randomized clinical trial was conducted at a tertiary center in China between December 2024 and May 2025. Children with PMNE and serum 25-hydroxyvitamin D (25(OH)D) levels below 30 ng/mL were randomly assigned to receive either 8 weeks of VDS (vitamin D3 soft capsules, 2400 IU/day) plus EA (VDS + EA group) or EA (EA group). The primary outcome was treatment response. Secondary outcomes included change in weekly frequency of wet nights, quality-of-life (QoL) scores and treatment satisfaction. Safety was assessed by recording treatment-emergent adverse events (TEAEs).
Results: A total of 304 children were enrolled, of whom 262 (130 in the VDS + EA group and 132 in the EA group) were included in the final analysis. Compared with the EA group, the VDS + EA group showed higher response rates (RR 1.22; 95% CI 1.01-1.49; P = 0.04), complete response rates (RR 1.54; 95% CI 1.10-2.15; P = 0.01), a greater reduction in weekly wet nights (median difference, 1; 95% CI, 0-2; P = 0.003), and greater improvements in QoL and treatment satisfaction. No statistically significant difference in the risk of TEAEs was observed between groups.